Induction of Response and Remission of Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in Patients With Moderately to Severely Active Ulcerative Colitis

Trial Profile

Induction of Response and Remission of Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Tacrolimus (Primary) ; Vedolizumab (Primary) ; Cotrimoxazole
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms COVET
  • Most Recent Events

    • 07 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 23 Mar 2017 Planned primary completion date changed from 1 Feb 2019 to 1 May 2019.
    • 23 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top